This site is intended for patients prescribed Simponi (golimumab). If you are a Healthcare Professional then go to the HCP site or if you are a member of the public, please visit our public site.


This site has been developed for patients who have been prescribed Simponi (golimumab). Here are some things you might like to know about your medication:

Simponi (golimumab) convenient dosing schedule

For Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Non-Radiographic Axial Spondyloarthritis (nr-axSpA) and Ankylosing Spondylitis (AS): same day every month

For Ulcerative Colitis (UC): once every 4 weeks after induction doses at week 0 and 2

Designed for you

The SmartJect pen was created in collaboration with patients and nurses


Why have I been prescribed Simponi  (golimumab)?

Simponi (golimumab) is for people with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Non-Radiographic Axial Spondyloarthritis (nr-axSpA), Ankylosing Spondylitis (AS) and Ulcerative Colitis (UC). It is prescribed when people have had limited success with painkillers, disease-modifying drugs and other medicines.

How does Simponi (golimumab) work?

Your immune system naturally produces a protein called tumour necrosis factor alpha (TNF-alpha). When your body produces too much TNF-alpha this can lead to:

  • For RA, PsA, nr-axSpA, AS: Inflammation and painful joints
  • For UC: Inflammation of your gut and the other symptoms of your condition

Simponi is an anti-TNF, this means that it works by blocking TNF-alpha:

  • For RA, PsA, nr-axSpA, AS: This reduces the inflammation in your body
  • For UC: This reduces the inflammation in your body

Better your understanding

Click on one of the boxes to learn more:


Rheumatoid Arthritis


Psoriatic Arthritis

Axial SpA

Axial Spondyloarthritis


Ulcerative Colitis

Rheumatoid Arthritis (RA)

In RA the body produces too muh TNF-alpha, making your body mistakenly start attacking the tissue lining your joints. This causes inflammation, making your joints painful and swollen, and may lead to joint damage in the long term.

Psoriatic Arthritis (PsA)

Psoriasis is a condition that causes areas of your skin to become red and swollen.

When people with psoriasis produce too much TNF-alpha, you can develop PsA. This causes your body to mistakenly start attacking the tissue lining your joints, making them painful and swollen.

PsA most commonly affects the fingers, toes, knees and elbows – but can occur in any joint. Dactylitis is the name used to describe when a finger or toe becomes swollen, caused by joints and tendons being inflamed at the same time.

Axial Spondyloarthritis (Axial SpA)

Axial SpA may be diagnosed as either AS (Ankylosing Spondylitis), or nr-axSpA (Non-Radiographic Axial Spondyloarthritis) if joint damage is not present on X-rays or does not meet certain criteria.

In AS and nr-axSpA the body produces too much TNF-alpha, making your body mistakenly start attacking the area where your ligaments attach to your spine. This causes inflammation and can lead to the vertebrae in your lower back fusing, causing pain and stiffness.

As well as your back, the hip, ankle, elbow, heel or shoulder joints can also be affected.

Ulcerative Colitis (UC)

Ulcerative Colitis is a type of inflammatory bowel disease. It is a long-term condition, but you will have periods when your symptoms are reduced (remission) and flares, when they will temporarily get worse. In people with UC, your body produces too much TNF-alpha, causing your immune system to mistakenly start attacking healthy tissue in your colon.

The exact cause of UC is unknown, but it is thought to be influenced by:

  • Your genes
  • An abnormal reaction to bacteria in your gut
  • An environmental trigger e.g. diet or stress


For further information about Simponi (golimumab) please contact our Medical Information Department at:

Medical Information Department

Merck Sharp & Dohme Ltd.

Hertford Road



EN11 9BU

Tel: 01992 467272


External link

The link you have selected is not under the review or control of MSD and, as such, the company does not endorse the content, its accuracy, or any practices or standards contained within it.

Please confirm you wish to follow this link.


  1. Kanai T et al. Korean J Intern Med 2014; 29(4): 409-15
  2. Olendzki BC et al. Nutr J 2014; 13(5): 1-7.
  3. Brown AC et al. Expert Rev. Gastroenterol. Hepatol 2011; 5(3): 411-25
  4. Pituch-Zdanowksa A et al. Prz Gastroenterol 2015; 10(3): 135-41.
  5. Oliviero F et al. Swiss Med Wkly 2015; 145: w14190.
  6. Clinton CM et al. Arthritis 2015; 2015: Article ID 708152.
  7. Narula N, Fedorak RN. Can J Gastroenterol 2008; 22 (5): 497-504
  8. Bilski J et al. BioMed Res Int 2014; Volume 2014 (Article ID 429031): 1-14.
  9. Benatti FB, Pedersen BK. Nat Rev Rheumatol 2015; 11: 86-97
  10. Nolte K et al. S Afr Fam Pract 2013; 55: 345-9
  11. Metsios GA et al. Expert Rev Clin Immunol 2015 [Epub ahead of print]
  12. Brophy S et al. Semin Arthritis Rheum 2013; 42: 619-26